A systematic literature review on the burden of diabetic ketoacidosis in type 2 diabetes mellitus
Wysham C, Bindal A, Levrat-Guillen F, et al.
Diabetes Obes Metab. Pub. online 3 Mar 2025.
Leggi
IA-2A positivity increases risk of progression within and across established stages of type 1 diabetes
Sims EK, Cuthbertson D, Ferrat LA, et al.
Diabetologia. Pub. online 28 Feb 2025.
Leggi
A new legal standard for medical malpractice
Aaron DG, Robertson CT, King LP, Sage WM
JAMA. Pub. online 26 Feb 2025.
Leggi
REVOCA CARENZA FARMACI GLP-1 AGONISTI RECETTORIALI
Carissime Socie e Carissimi Soci, alleghiamo la recente comunicazione della Direzione Medica di Novo Nordisk che annuncia la revoca della carenza del farmaco GLP-1 agonisti recettoriali per tutti i dosaggi e senza limitazioni all’inserimento di nuovi casi di persone con diabete. Potrete visionare la lettera al seguente link. Con soddisfazione…
Leggi
Differential treatment effects on β-cell function using model-based parameters in type 2 diabetes: results from the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE)
Utzschneider KM, Tripputi M, Butera NM, et al.
Diabetes Care. 2025:dc242419.
Leggi
Sex-specific optimal cut-off points for metabolic health indicators to predict incident type 2 diabetes mellitus
Xing Z, Xiao M, Schocken DD, et al.
Nutr Metab Cardiovasc Dis. Pub. online 27 Feb 2025.
Leggi
Sodium-glucose cotransporter-2 inhibitors and arrhythmias: a meta-analysis of 38 randomized controlled trials
Jaiswal V, Ang SP, Kumar D, et al.
JACC Adv. 2025;4(3):101615.
Leggi
Prognostic benefit of GLP-1 RA addition to SGLT2i in patients with ASCVD and heart failure: a cohort study
Chen SY, Wu JY, Liao KM, Lin YM
Eur Heart J Cardiovasc Pharmacother. 2025:pvaf014.
Leggi
Finerenone and outpatient worsening heart failure with mildly reduced or preserved ejection fraction: a secondary analysis of the FINEARTS-HF randomized clinical trial
Cunningham JW, Chatur S, Claggett BL, et al.
JAMA Cardiol. 2025:e250016.
Leggi
The effect of empagliflozin on non-alcoholic fatty liver disease-related parameters in patients with type 2 diabetes mellitus: a randomized controlled trial
Shojaei F, Erfanifar A, Kalbasi S, et al.
BMC Endocr Disord. 2025;25(1):52.
Leggi